Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Financials
52W LOW $114.0252W HIGH $157.29
Volume
5.80 M
Value Traded
909.57 M
Short % Float
1.48%
+4.52%Week
+4.39%1 Month
+15.05%3 Month
+8.73%6 Month
+92.58%5 Year
+24,824.73%All Time
Cash Data
- Cash FlowProfitable
- SEC Filing
Key Stats
Market Cap
187.44 B
EPS (TTM)
-2.61
P/E Ratio
-
Ent. Value
212.93 B
Total Shares
1.24 B
Float Shares
1.24 B
Insiders
0.17%
Institutions
92.60%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
GILD Catalyst Timeline
Dated clinical, regulatory and corporate events for Gilead Sciences, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Gilead Sciences, Inc.
531Total events
20Upcoming
255Tier-1 (high impact)
2018 to 2028Coverage
Upcoming catalysts 2
Event history 50
▲Partnership / LicenseLenacapavirApprovedCorporate
Gilead expands six royalty-free voluntary licensing agreements to include once-yearly lenacapavir for HIV prevention, covering 120 high-incidence countries
HIV prevention (PrEP)source ↗
▲Partnership / LicenseLenacapavirApprovedCorporate
Gilead and PAHO agreement to accelerate access to twice-yearly lenacapavir for HIV prevention across Latin America and the Caribbean
HIV prevention (PrEP)source ↗
▲Partnership / LicenseLenacapavirApprovedCorporate
Gilead agreement with Pan American Health Organization to accelerate access to twice-yearly lenacapavir for PrEP across PAHO Member States
HIV prevention (PrEP)source ↗
▲FDA ApprovalBixlenvoApprovedFDA Decision
FDA approved Bixlenvo for HIV-1 infection in virologically suppressed adults
HIV-1 infection in adults who are virologically suppressedsource ↗
▲Full ResultsBixlenvoApprovedClinical Data
ARTISTRY-1 results published in The Lancet
HIV-1 infection in adults who are virologically suppressedsource ↗
▲EU ApprovalTrodelvyDiscontinuedEx-US Regulatory
European Commission granted marketing authorization for Trodelvy plus pembrolizumab in first-line PD-L1-positive metastatic TNBC
first-line metastatic triple-negative breast cancer (PD-L1-positive, CPS ≥10)source ↗
▲FDA Filing AcceptedYeztugoApprovedRegulatory Filing
FDA accepted sNDA for Yeztugo (lenacapavir) 300-mg tablets as once-weekly oral PrEP
HIV pre-exposure prophylaxissource ↗
▲Topline ReadoutIslatravir/lenacapavirClinical Data
Positive Phase 3 results from ISLEND-1 trial of islatravir and lenacapavir regimen
HIVsource ↗
▲FDA ApprovalHepcludexApprovedFDA Decision
FDA accelerated approval for Hepcludex for chronic HDV
chronic hepatitis delta virus infectionsource ↗
▲FDA ApprovalTrodelvyDiscontinuedFDA Decision
FDA approval of Trodelvy for 1L mTNBC
first-line metastatic triple-negative breast cancersource ↗
▲EU ApprovalTrodelvyDiscontinuedEx-US Regulatory
European Commission marketing authorization for Trodelvy as monotherapy for 1L mTNBC
unresectable locally advanced or metastatic triple-negative breast cancersource ↗
▲CHMP Positive OpinionTrodelvyDiscontinuedEx-US Regulatory
CHMP positive opinion for Trodelvy in combination with Keytruda for 1L mTNBC
unresectable locally advanced or metastatic triple-negative breast cancersource ↗
▼Trial DiscontinuedTrodelvyDiscontinuedTrial
Discontinuation of Phase 3 EVOKE-03 study of Trodelvy + Keytruda in 1L NSCLC
first-line metastatic non-small cell lung cancersource ↗
▲Topline ReadoutLivdelziApprovedClinical Data
Positive Phase 3 results from IDEAL study of Livdelzi
primary biliary cholangitissource ↗
▲FDA Filing AcceptedYeztugoApprovedRegulatory Filing
FDA accepted sNDA for Yeztugo (lenacapavir) 300-mg tablets for HIV PrEP
HIV pre-exposure prophylaxissource ↗
▲Topline ReadoutIslatravir/lenacapavirClinical Data
Positive Phase 3 results from ISLEND-1 trial of islatravir and lenacapavir
HIVsource ↗
▲FDA ApprovalTrodelvyDiscontinuedFDA Decision
FDA approval of Trodelvy for 1L mTNBC
metastatic triple-negative breast cancersource ↗
▲EU ApprovalTrodelvyDiscontinuedEx-US Regulatory
European Commission marketing authorization for Trodelvy as monotherapy for 1L mTNBC
metastatic triple-negative breast cancersource ↗
▲CHMP Positive OpinionTrodelvyDiscontinuedEx-US Regulatory
CHMP positive opinion for Trodelvy in combination with Keytruda for 1L mTNBC
metastatic triple-negative breast cancersource ↗
▼Trial DiscontinuedTrodelvyDiscontinuedTrial
Discontinuation of Phase 3 EVOKE-03 study of Trodelvy in 1L mNSCLC
metastatic non-small cell lung cancersource ↗
▲Topline ReadoutLivdelziApprovedClinical Data
Positive Phase 3 results from IDEAL study of Livdelzi in PBC
primary biliary cholangitissource ↗
▲EU ApprovalTrodelvyDiscontinuedEx-US Regulatory
Recent EC approval of Trodelvy as monotherapy in first-line metastatic TNBC
first-line metastatic triple-negative breast cancer (PD-L1-negative, not candidates for PD-1/PD-L1 inhibitors)source ↗
▲Oral PresentationLenacapavirApprovedPresentation
Detailed outcomes from ISLEND-2 presented at AIDS 2026
HIVsource ↗
▲CHMP Positive OpinionTrodelvyDiscontinuedEx-US Regulatory
CHMP positive opinion for Trodelvy plus Keytruda in PD-L1 positive first-line metastatic TNBC
PD-(L)1-positive first-line metastatic triple-negative breast cancersource ↗
◆Oral PresentationIslatravir/lenacapavirPresentation
Detailed outcomes from ISLEND-1 and ISLEND-2 trials presented at AIDS 2026
HIVsource ↗
◆Oral PresentationLenacapavirApprovedPresentation
Detailed outcomes from ISLEND-1 and ISLEND-2 trials presented at AIDS 2026
HIVsource ↗
▲Primary Endpoint MetIslatravir/lenacapavirClinical Data
ISLEND-2 met primary endpoint: noninferior virologic suppression at Week 48
HIVsource ↗
▲Full ResultsIslatravir/lenacapavirClinical Data
Week 48 full results from ISLEND-1 announced
HIVsource ↗
▲Partnership / LicenseLenacapavirApprovedCorporate
Expanded partnership with PEPFAR and Global Fund for lenacapavir access
HIV prevention (PrEP)source ↗
◆Other Regulator MilestoneLenacapavirApprovedEx-US Regulatory
Ongoing discussions with PAHO to expand lenacapavir access in Latin America
HIV prevention (PrEP)source ↗
▲Primary Endpoint MetLenacapavirApprovedClinical Data
Week 48 primary endpoint met: noninferiority to standard of care
HIVsource ↗
▲FDA ApprovalTrodelvyDiscontinuedFDA Decision
FDA approval for first-line treatment of mTNBC
metastatic triple-negative breast cancersource ↗
▲EU ApprovalTrodelvyDiscontinuedEx-US Regulatory
European Commission approves Trodelvy as first-line treatment for metastatic triple-negative breast cancer patients not candidates for PD-(L)1 inhibitors
metastatic triple-negative breast cancersource ↗
▲FDA Filing AcceptedYeztugoApprovedRegulatory Filing
FDA accepts NDA for Yeztugo
HIV preventionsource ↗
◆Poster PresentationKITE-753Presentation
Updated safety and efficacy results of KITE-753
relapsed/refractory B-cell lymphomasource ↗
◆Poster Presentationbrexu-celPresentation
Cost-effectiveness analysis of brexucabtagene autoleucel in Singapore
relapsed or refractory B-cell precursor acute lymphoblastic leukemiasource ↗
◆Poster PresentationPresentation
Follow-up-time-adjusted non-relapse mortality following CAR T-cell therapy within clinical trials
non-Hodgkin lymphomasource ↗
◆Poster Presentationanito-celFiledPresentation
Anito-cel clinical trial manufacturing experience
relapsed/refractory or newly diagnosed multiple myelomasource ↗
◆Poster Presentationaxi-celPresentation
Cost-effectiveness of axi-cel in Taiwanese patients after first-line treatment
relapsed/refractory diffuse large B-cell lymphoma and high-grade B-cell lymphomasource ↗
◆Poster Presentationaxi-celPresentation
Cost-effectiveness of axi-cel in Taiwanese patients after two lines of systemic therapy
relapsed/refractory diffuse large B-cell lymphomasource ↗
◆Poster PresentationPresentation
CAR T-cell therapy in clinical routine: quantification of real-world hospital resource use in Germany
non-Hodgkin lymphomasource ↗
▲Topline ReadoutIslatravir/lenacapavirClinical Data
Positive topline results from two Phase 3 studies
HIVsource ↗
Past FDA Catalysts and PDUFA Decisions
How GILD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-08-27 | bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) | PDUFA Date Approved | PDUFA |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
A84 / 100
Pipeline Score
$39.9B
Pipeline Value
$130.4B
Commercial Value
Fair Value
Valuation Signal
53
Drugs Scored
0.7x
rNPV / MCap
Top 1%
Large Pharma(rank 8 of 660)
Percentile Rank
Gilead Sciences, Inc. earns an A-grade pipeline score (84/100), with $39.9B risk-adjusted pipeline value, led by Truvada in HIV/AIDS (Phase 3).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $30.5B x 4.3 = $130.4B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Biktarvy | $14.8B | $13.9B | +6.2% |
| Descovy | $3.3B | $2.4B | +34.9% |
| Trodelvy | $1.6B | $1.3B | +19% |
| Yescarta | $1.4B | $1.6B | -10.3% |
| Genvoya | $1.3B | $1.7B | -21.1% |
| Sofosbuvir/Velpatasvir | $1.2B | $1.4B | -16.5% |
| Vemlidy | $1.1B | $996M | +9.6% |
| Odefsey | $1.0B | $1.2B | -15.5% |
| Veklury | $655M | $1.5B | -54.9% |
| Symtuza - Revenue share | $532M | $521M | +2.1% |
| AmBisome | $489M | $507M | -3.6% |
| Tecartus | $319M | $367M | -13.1% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Truvada Small moleculeMarketedNCT02616783 | HIV-1 Infection | Phase 3 | COMPLETED | 167 | Mar 21, 2018 |
Clinical Trial Results
Readouts, endpoints and source filings for every GILD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| islatravir and lenacapavir | HIV | Phase 3 | 2026-07-21 | the primary endpoint results at Week 48 showed that the investigational once-weekly oral single-tablet HIV treatment regimen of islatravir 2 mg/lenacapRead More | Investigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral TherapyRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| O'Day Daniel PatrickDirector, Officer (Chairman & CEO) | Sell | -12,000 569,683 held | $147.72 | 10/01/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in GILD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Sofinnova Investments, Inc. | 2.2 % (-71.1 %) | 43.35 M | 343.10 K | -72.6% ( -909.21 K) |
GILD Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How GILD ranks across every disease it competes in
Competitive Position is a premium feature
See how GILD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialGILD News
GILDCognizant Expands AI-Enabled DevOps Capabilities for Gilead Sciences
Cognizant has announced a five-year extension of its partnership with Gilead Sciences to enhance DevOps capabilities and implement AI tools. This collaboration aims to streamline processes and improve operational efficiency in Gilead's technology programs. The agreement builds on over a decade of support for Gilead's IT infrastructure and analytics.
Read more →GILDGilead Accelerates Global Access Planning for Investigational Once-Yearly Lenacapavir for HIV Prevention
Gilead Sciences has expanded its royalty-free licensing agreements for lenacapavir to include a once-yearly formulation for HIV prevention. This initiative aims to enhance global access to pre-exposure prophylaxis (PrEP) in 120 high-incidence countries, primarily targeting low- and lower-middle-income regions. The agreements will facilitate manufacturing readiness and technology transfer.
Read more →GILDGilead and PAHO Announce Milestone Partnership to Accelerate Access to Twice-Yearly Lenacapavir for HIV Prevention Across Latin America and the Caribbean
Gilead Sciences has partnered with the Pan American Health Organization (PAHO) to enhance access to lenacapavir, a long-acting HIV prevention treatment, across Latin America and the Caribbean. This agreement aims to utilize PAHO's Regional Revolving Funds to create a coordinated pathway for distributing the medication. The initiative supports local efforts to combat HIV through pre-exposure prophylaxis (PrEP).
Read more →GILDGilead Opens State-of-the-Art Research Center to Advance the Next Generation of Medicines
Gilead Sciences has inaugurated a new 182,000-square-foot Research Center in Foster City, California, aimed at enhancing its research capabilities in oncology and inflammation. This facility is part of a broader $32 billion investment in U.S. research and development through 2030, which will create 3,000 jobs. The center is designed to foster collaboration among scientists and advance the development of innovative medicines.
Read more →GILDU.S. FDA Approves Gilead’s Bixlenvo™, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens
Gilead Sciences has received FDA approval for Bixlenvo™, a new once-daily single tablet regimen for adults with HIV who are virologically suppressed. This treatment is particularly beneficial for those on complex regimens and unable to use existing STRs. Bixlenvo™ combines bictegravir and lenacapavir, providing a novel option in HIV management.
Read more →GILDGilead Sciences to Present at Upcoming Third Quarter 2026 Investor Conferences
Gilead Sciences, Inc. has announced its participation in several upcoming investor conferences. Executives will present at the Wells Fargo Annual Healthcare Conference, Cantor Global Healthcare Conference, and Morgan Stanley Global Healthcare Conference in September 2026. Live webcasts of these presentations will be available for investors.
Read more →GILDEuropean Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
Gilead Sciences has received marketing authorization from the European Commission for Trodelvy in combination with Keytruda for treating adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC). This authorization applies to patients who have not previously received systemic therapy and whose tumors express PD-L1. This development expands treatment options for this challenging cancer type.
Read more →GILDCORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
Gilead Sciences has announced its corrected financial results for Q2 2026, highlighting a 10% increase in product sales excluding Veklury, totaling $7.6 billion. Notably, Odefsey sales in Europe were adjusted to $58 million, up from a previously reported $28 million. Additionally, Biktarvy sales rose by 7% year-over-year, indicating positive growth.
Read more →GILDGilead Sciences Announces Second Quarter 2026 Financial Results
Gilead Sciences reported a strong second quarter for 2026, achieving a 10% year-over-year revenue growth primarily driven by its HIV portfolio, Trodelvy, and Livdelzi. The company noted a 12% increase in HIV sales, which reflects ongoing strength in treatment and growth in its PrEP business. This performance has led to an upward revision of revenue expectations for the year.
Read more →GILDCHMP Recommends Gilead’s Trodelvy® Plus Keytruda® in PD-(L)1-Positive First-Line Metastatic Triple-Negative Breast Cancer
Gilead Sciences has received a positive recommendation from the CHMP for Trodelvy in combination with Keytruda for treating adult patients with unresectable locally advanced or metastatic triple-negative breast cancer. This marks a significant step towards marketing authorization in the EU, enhancing treatment options for patients who have not yet received therapy.
Read more →GILDGilead Sciences to Release Second Quarter 2026 Financial Results on Tuesday, August 4, 2026
Gilead Sciences, Inc. will announce its second quarter 2026 financial results on August 4, 2026, after market close. Following the release, management will host a webcast at 4:30 p.m. Eastern Time to discuss the results and provide a business update. The webcast will be available for live viewing and later archived.
Read more →GILDInvestigational Once-Weekly Oral HIV Treatment Regimen of Islatravir and Lenacapavir Maintained Virological Suppression in Adults With HIV Who Switched Antiretroviral Therapy
Gilead Sciences and Merck announced positive results from the Phase 3 ISLEND-1 and ISLEND-2 trials of an investigational once-weekly oral HIV treatment regimen. The regimen, consisting of islatravir and lenacapavir, demonstrated maintained virological suppression in adults who switched their antiretroviral therapy. These findings will be presented at the upcoming International AIDS Conference.
Read more →GILDGilead to Present New HIV Research at AIDS 2026 Across Prevention, Treatment and Cure
Gilead Sciences, Inc. will participate in the 26th International AIDS Conference in Rio de Janeiro from July 26-31. The company plans to present new scientific data from its HIV research and development programs. Additionally, Gilead will provide updates on its strategic initiatives and key collaborations during the event.
Read more →GILDU.S. FDA Approves Trodelvy® for First-Line Treatment of Metastatic Triple-Negative Breast Cancer
Gilead Sciences announced that the FDA has approved Trodelvy for first-line treatment of metastatic triple-negative breast cancer (mTNBC). This approval allows Trodelvy to be used as a single agent for patients who cannot undergo surgery. The drug is a Trop-2-directed antibody-drug conjugate, marking a significant advancement in treatment options for this patient population.
Read more →GILDEuropean Commission Approves Trodelvy® as a First-Line Treatment for Metastatic Triple-Negative Breast Cancer Patients Not Candidates for PD-(l)1 Inhibitors
The European Commission has approved Trodelvy® as a first-line treatment for patients with metastatic triple-negative breast cancer who are not candidates for PD-(l)1 inhibitors. This approval offers a new therapeutic option for a challenging patient population, enhancing treatment accessibility and potential outcomes.
Read more →GILDU.S. FDA Accepts Gilead’s Application for Investigational Once-Weekly Oral Yeztugo, Potentially the First Long-Acting Pill for HIV Prevention
The U.S. FDA has accepted Gilead's application for Yeztugo, an investigational once-weekly oral medication. If approved, Yeztugo could be the first long-acting pill for HIV prevention, potentially improving adherence among patients. This development marks a significant step in HIV prevention strategies.
Read more →GILDGilead and Merck Announce Positive Topline Results From Two Phase 3 Studies Evaluating Islatravir/Lenacapavir, an Oral Once-Weekly HIV Treatment
Gilead and Merck have reported positive topline results from two Phase 3 studies evaluating Islatravir/Lenacapavir, a new oral treatment for HIV. This treatment is designed to be taken once weekly, potentially improving adherence among patients. The results indicate significant efficacy, marking a promising advancement in HIV therapy.
Read more →GILDGilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
Gilead's Livdelzi® (seladelpar) has demonstrated statistically significant composite alkaline phosphatase (ALP) normalization in the Phase 3 IDEAL trial for patients with Primary Biliary Cholangitis (PBC). This result indicates a promising advancement in the treatment of PBC, potentially enhancing patient outcomes. The trial's findings may lead to broader therapeutic applications for Livdelzi®.
Read more →GILDGermany can produce biotech winners. Europe must back them better.
Germany is positioned to produce biotech champions due to its strong scientific infrastructure and capital availability, as evidenced by Gilead's acquisition of Tubulis. However, to enhance its global competitiveness, the country requires deeper funding pools and more flexible investment regulations. The collaboration between local and international investors is crucial for scaling successful biotech companies.
Read more →GILDThe top 5 highest paid pharma CEOs in 2025
In 2025, the top five highest paid pharma CEOs earned a combined $157.8 million, marking a 24% increase from the previous year. Eli Lilly's David Ricks led with a compensation of $36.7 million, driven by significant company growth and stock awards. Other notable CEOs include J&J's Joaquin Duato and AbbVie's Robert Michael, who also saw substantial pay increases amid industry pressures.
Read more →About Gilead Sciences, Inc.
Headquarters333 LAKESIDE DR, FOSTER CITY, CA, 94404
BIOPHARMAWATCH ELITE PLUS
Trade the next GILD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime